Skip to main content
MRNA logo
MRNA
(NASDAQ)
Moderna, Inc.
$48.12-- (--)
Loading... - Market loading

Moderna (MRNA) Company Profile

Complete business overview, executive team, trading details, and corporate information.

Moderna, Inc.
MRNANasdaq Stock MarketHealthcareBiotechnology

About Moderna

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Company Information

CEOStéphane Bancel
Founded2010
Employees4,700
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNasdaq Stock Market (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Phone617 714 6500
Address
325 Binney Street Cambridge, Massachusetts 02142 United States

Corporate Identifiers

CUSIP60770K107
ISINUS60770K1079
SIC2836

Leadership Team & Key Executives

Stéphane Bancel
Chief Executive Officer
James Mock
Chief Financial Officer
Lavina Talukdar
Head of Investor Relations